Evidence map›Paper›PMID 33024658›Full record

ReviewJournal of bone oncology2020

c-Met expression in renal cell carcinoma with bone metastases.

Rita Silva Paiva, Inês Gomes, Sandra Casimiro, Isabel Fernandes, Luís Costa

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of bone oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Retrospective study assessing the role of the androgen receptor in clear cell renal cell cancer patients treated with VEGFR inhibitors in monotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Rita Silva PaivaOncology Division, Hospital de Santa Maria, CHULN, 1649-035 Lisboa, Portugal.
Inês GomesInstituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal.
Sandra CasimiroInstituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal.
Isabel FernandesOncology Division, Hospital de Santa Maria, CHULN, 1649-035 Lisboa, Portugal.
Luís CostaOncology Division, Hospital de Santa Maria, CHULN, 1649-035 Lisboa, Portugal.
University of Lisbon · PTHospital de Santa Maria · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocyte growth factor (HGF)/c-Met pathway is implicated in embryogenesis and organ development and differentiation. Germline or somatic mutations, chromosomal rearrangements, gene amplification, and transcriptional upregulation in

Indexed as

ALK, anaplastic lymphoma kinase geneAR, androgen receptorATP, adenosine triphosphateAXL, AXL Receptor Tyrosine KinaseBME, bone microenvironmentBMPs, bone morphogenetic proteinsBMs, bone metastasesBone metastasesBPs, BisphosphonatesBTAs, Bone-targeting agentsCaSR, calcium/calcium-sensing receptorCCL20, chemokine (C-C motif) ligand 20ccRCC, clear-cell RCCCI, confidence intervalCRPC, Castration Resistant Prostate CancerCSC, cancer stem cellsCTC, circulating tumor cellsEMA, European Medicines AgencyEMT, epithelial-to-mesenchymal transitionFDA, US Food and Drug AdministrationFLT-3, FMS-like tyrosine kinase 3GEJ, Gastroesophageal JunctionHCC, Hepatocellular CarcinomaHGF/c-MetHGF, hepatocyte growth factorHIF, hypoxia-inducible factorsHR, hazard ratioIGF2BP3, insulin mRNA Binding Protein-3IGF, insulin-like growth factorIL, interleukinIRC, independent review committeesKidney cancerKIT, tyrosine-protein kinase KITmAb, monoclonal antibodiesM-CSF, macrophage colony-stimulating factorMET, MET proto-oncogene, receptor tyrosine kinaseNSCLC, non-small cell lung carcinomaORR, overall response rateOS, overall survivalPDGF, platelet-derived growth factorPFS, progression free survivalpRCC, papillary renal cell carcinomaPTHrP, parathyroid hormone-related peptideRANKL, receptor activator of nuclear factor-κB ligandRCC, renal cell carcinomaRET, rearranged during transfection proto-oncogeneROS, proto-oncogene tyrosine-protein kinase ROSRTK, receptor tyrosine kinaseSCLC, Squamous Cell Lung CancerSREs, skeletal-related eventsSSE, symptomatic skeletal eventsTargeted therapyTGF-β, transforming growth factor-βTIE-2, Tyrosine-Protein Kinase Receptor TIE-2TKI, tyrosine kinase inhibitorTRKB, Tropomyosin receptor kinase BVEGFR, vascular endothelial growth factor receptorVHL, Hippel-Lindau tumor suppressor geneZA, zoledronic acid

Identifiers

PMID33024658
PMCPMC7527574
OpenAlexW3087654736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.